Exercise more than doubled the odds of shaking off depression

Depression is common, existing treatments do not work for everyone, and exercise is perennially proposed as an add-on or alternative. Previous network analyses have compared exercise modalities against each other, which answers a different question from the basic one most people ask: does structured exercise beat doing nothing? This pairwise analysis was designed to quantify exactly that, exercise versus no exercise, using rigorous definitions of what counts as a control group and updated methods. Getting that comparison right matters, because how the control condition is defined can change the apparent size of the effect considerably.

The authors searched the literature up to November 2025, screening 10,123 records and including 40 randomised controlled trials of structured exercise versus no exercise for depression symptoms. Results were pooled with random-effects models, using odds ratios for remission and standardised mean differences for depression scores, and the consistency of results across studies was assessed. They also graded the certainty of the evidence using the GRADE approach and ran subgroup analyses by supervision and by type of control condition, which ranged from waitlists to pharmacotherapy.

Exercise was associated with 2.40 times the odds of remission compared with control conditions, and the number needed to treat was 2.1, meaning roughly one extra remission for every two people treated. Depression scores also fell, by a pooled standardised mean difference of 0.96, which the authors describe as clinically meaningful. Effects were larger for supervised exercise and against passive controls such as waitlists than against active comparators such as drug treatment. Certainty was graded moderate for remission but low for symptom scores, where the studies disagreed with each other substantially and the prediction interval crossed zero, meaning exercise may not benefit all future populations.

The direction of the result agrees with a large existing literature on exercise and mood, but the honest accounting of weaknesses is what distinguishes this synthesis. Only 12 of the 40 trials were at low risk of bias, most followed people for 16 weeks or less, and control conditions ranged from waitlists to pharmacotherapy, which makes the pooled figure a blend of quite different comparisons. The remission finding stands on firmer ground than the symptom-score finding. The authors themselves call for large, high-quality trials with standardised outcomes and longer follow-up before clinical recommendations are made.

For anyone managing low mood, this is a reason to take movement seriously as part of the picture rather than as a token gesture: across these trials, people assigned to structured exercise reached remission markedly more often than those who were not. The strongest results came from supervised programmes and from comparisons against doing nothing, so the finding says more about exercise versus inactivity than exercise versus medication. It is information, not a treatment plan, and anyone weighing options for depression is weighing something these data alone cannot settle.